

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer ID6138

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
 Company Merck Sharp & Dohme (pembrolizumab) Patient/carer groups Black Health Agency for Equality Cancer Black Care Cancer52 Eve Appeal Go Girls Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Wellbeing of Women Women's Health Concern 	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Healthcare professional groups Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland British Association of Surgical Oncology British Geriatrics Society British Gynaecological Cancer Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society for Clinical Cytology British Society for Colposcopy and Cervical Pathology 	 Possible comparator companies None Relevant research groups Cochrane Gynaecological Cancer Group Cochrane UK Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Pro-Cancer Research Fund Associated Public Health groups Public Health Wales

Final stakeholder list for the evaluation of pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer ID6138

Issue date: January 2025



Consultees	Commentators (no right to submit or appeal)
 Cancer Research UK National Forum of Gynaecological Oncology Nurses Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Obstetricians & Gynaecologists Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society 	UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer ID6138

Issue date: January 2025



Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.